Amniotic fluid stem cells: A promising therapeutic resource for cell-based regenerative therapy

Ivana Antonucci, Andrea Pantalone, Stefano Tetè, Vincenzo Salini, Cesar V. Borlongan, David Hess, Liborio Stuppia

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Stem cells have been proposed as a powerful tool in the treatment of several human diseases, both for their ability to represent a source of new cells to replace those lost due to tissue injuries or degenerative diseases, and for the ability of produce trophic molecules able to minimize damage and promote recovery in the injured tissue. Different cell types, such as embryonic, fetal or adult stem cells, human fetal tissues and genetically engineered cell lines, have been tested for their ability to replace damaged cells and to restore the tissue function after transplantation. Amniotic fluid -derived Stem cells (AFS) are considered a novel resource for cell transplantation therapy, due to their high renewal capacity, the "in vitro" expression of embryonic cell lineage markers, and the ability to differentiate in tissues derived from all the three embryonic layers. Moreover, AFS do not produce teratomas when transplanted into animals and are characterized by a low antigenicity, which could represent an advantage for cell transplantation or cell replacement therapy. The present review focuses on the biological features of AFS, and on their potential use in the treatment of pathological conditions such as ischemic brain injury and bone damages.

Original languageEnglish (US)
Pages (from-to)1846-1863
Number of pages18
JournalCurrent Pharmaceutical Design
Volume18
Issue number13
DOIs
StatePublished - May 1 2012

Fingerprint

Amniotic Fluid
Stem Cells
Cell Transplantation
Cell- and Tissue-Based Therapy
Fetal Stem Cells
Adult Stem Cells
Teratoma
Cell Lineage
Therapeutics
Embryonic Stem Cells
Brain Injuries
Fetus
Transplantation
Bone and Bones
Cell Line
Wounds and Injuries

Keywords

  • Amniotic fluid
  • Amniotic fluid-derived mesenchymal stem cells
  • Cell-based therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Amniotic fluid stem cells : A promising therapeutic resource for cell-based regenerative therapy. / Antonucci, Ivana; Pantalone, Andrea; Tetè, Stefano; Salini, Vincenzo; Borlongan, Cesar V.; Hess, David; Stuppia, Liborio.

In: Current Pharmaceutical Design, Vol. 18, No. 13, 01.05.2012, p. 1846-1863.

Research output: Contribution to journalReview article

Antonucci, I, Pantalone, A, Tetè, S, Salini, V, Borlongan, CV, Hess, D & Stuppia, L 2012, 'Amniotic fluid stem cells: A promising therapeutic resource for cell-based regenerative therapy', Current Pharmaceutical Design, vol. 18, no. 13, pp. 1846-1863. https://doi.org/10.2174/138161212799859602
Antonucci, Ivana ; Pantalone, Andrea ; Tetè, Stefano ; Salini, Vincenzo ; Borlongan, Cesar V. ; Hess, David ; Stuppia, Liborio. / Amniotic fluid stem cells : A promising therapeutic resource for cell-based regenerative therapy. In: Current Pharmaceutical Design. 2012 ; Vol. 18, No. 13. pp. 1846-1863.
@article{cf1cd1c6b1c1472f8e85f18e2d10a437,
title = "Amniotic fluid stem cells: A promising therapeutic resource for cell-based regenerative therapy",
abstract = "Stem cells have been proposed as a powerful tool in the treatment of several human diseases, both for their ability to represent a source of new cells to replace those lost due to tissue injuries or degenerative diseases, and for the ability of produce trophic molecules able to minimize damage and promote recovery in the injured tissue. Different cell types, such as embryonic, fetal or adult stem cells, human fetal tissues and genetically engineered cell lines, have been tested for their ability to replace damaged cells and to restore the tissue function after transplantation. Amniotic fluid -derived Stem cells (AFS) are considered a novel resource for cell transplantation therapy, due to their high renewal capacity, the {"}in vitro{"} expression of embryonic cell lineage markers, and the ability to differentiate in tissues derived from all the three embryonic layers. Moreover, AFS do not produce teratomas when transplanted into animals and are characterized by a low antigenicity, which could represent an advantage for cell transplantation or cell replacement therapy. The present review focuses on the biological features of AFS, and on their potential use in the treatment of pathological conditions such as ischemic brain injury and bone damages.",
keywords = "Amniotic fluid, Amniotic fluid-derived mesenchymal stem cells, Cell-based therapy",
author = "Ivana Antonucci and Andrea Pantalone and Stefano Tet{\`e} and Vincenzo Salini and Borlongan, {Cesar V.} and David Hess and Liborio Stuppia",
year = "2012",
month = "5",
day = "1",
doi = "10.2174/138161212799859602",
language = "English (US)",
volume = "18",
pages = "1846--1863",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Amniotic fluid stem cells

T2 - A promising therapeutic resource for cell-based regenerative therapy

AU - Antonucci, Ivana

AU - Pantalone, Andrea

AU - Tetè, Stefano

AU - Salini, Vincenzo

AU - Borlongan, Cesar V.

AU - Hess, David

AU - Stuppia, Liborio

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Stem cells have been proposed as a powerful tool in the treatment of several human diseases, both for their ability to represent a source of new cells to replace those lost due to tissue injuries or degenerative diseases, and for the ability of produce trophic molecules able to minimize damage and promote recovery in the injured tissue. Different cell types, such as embryonic, fetal or adult stem cells, human fetal tissues and genetically engineered cell lines, have been tested for their ability to replace damaged cells and to restore the tissue function after transplantation. Amniotic fluid -derived Stem cells (AFS) are considered a novel resource for cell transplantation therapy, due to their high renewal capacity, the "in vitro" expression of embryonic cell lineage markers, and the ability to differentiate in tissues derived from all the three embryonic layers. Moreover, AFS do not produce teratomas when transplanted into animals and are characterized by a low antigenicity, which could represent an advantage for cell transplantation or cell replacement therapy. The present review focuses on the biological features of AFS, and on their potential use in the treatment of pathological conditions such as ischemic brain injury and bone damages.

AB - Stem cells have been proposed as a powerful tool in the treatment of several human diseases, both for their ability to represent a source of new cells to replace those lost due to tissue injuries or degenerative diseases, and for the ability of produce trophic molecules able to minimize damage and promote recovery in the injured tissue. Different cell types, such as embryonic, fetal or adult stem cells, human fetal tissues and genetically engineered cell lines, have been tested for their ability to replace damaged cells and to restore the tissue function after transplantation. Amniotic fluid -derived Stem cells (AFS) are considered a novel resource for cell transplantation therapy, due to their high renewal capacity, the "in vitro" expression of embryonic cell lineage markers, and the ability to differentiate in tissues derived from all the three embryonic layers. Moreover, AFS do not produce teratomas when transplanted into animals and are characterized by a low antigenicity, which could represent an advantage for cell transplantation or cell replacement therapy. The present review focuses on the biological features of AFS, and on their potential use in the treatment of pathological conditions such as ischemic brain injury and bone damages.

KW - Amniotic fluid

KW - Amniotic fluid-derived mesenchymal stem cells

KW - Cell-based therapy

UR - http://www.scopus.com/inward/record.url?scp=84860111984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860111984&partnerID=8YFLogxK

U2 - 10.2174/138161212799859602

DO - 10.2174/138161212799859602

M3 - Review article

C2 - 22352751

AN - SCOPUS:84860111984

VL - 18

SP - 1846

EP - 1863

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 13

ER -